Impact of COVID-19 Infection on the Incidence of Ventilator-acquired Infections (COVAPID)

April 17, 2026 updated by: University Hospital, Lille

Impact of SARS-CoV-2 Infection on the Incidence of Ventilator-acquired Infections

Observational cohort study aiming at comparing the incidence of ventilator-associated lower respiratory tract infections between COVID-19 patients and two control groups: one with influenza pneumonia and the other with no viral pneumonia.

Study Overview

Status

Completed

Conditions

Detailed Description

COVAPID is a multicenter cohort study with two retrospective control groups. No intervention will be performed in included patients, only patient characteristics and data on VA-LRTI will be collected.

Patients with confirmed SARS-CoV-2 community-acquired pneumonia, admitted to the participating ICUs from the start of COVID epidemic will be eligible for this study. Those admitted before the beginning of this study will be included retrospectively, and those admitted after the beginning of the study will be included prospectively. 10-20 patients per center will be included in this group. SARSCoV2 infection will be confirmed by a nasopharyngeal PCR or respiratory secretions (tracheal aspirate or bronchoalveolar lavage) PCR. Two retrospective groups will be constituted in order to give some insight of potential impact of SARS-CoV2 infection on the incidence of VALRTI :1) Influenza group : patients with influenza (A or B) community-acquired pneumonia. All patients with influenza community acquired pneumonia and admitted in the same ICU will be eligible in this group.

The number of patients included in this group per center will be similar as that of patients included in the SARS-CoV-2 pneumonia group (10-20 patients). These consecutive patients will by identified using the files of Virology Lab. The first included patient will be the last of the current influenza season (2019-2020), and others will be taken consecutively back to 2019 of 2018 if necessary. PCR (nasopharyngeal or respiratory secretions) confirmation of influenza (A ou B) is required for patients in this group. 2) No viral infection group: patients with no viral community acquired pneumonia. All patients receiving invasive mechanical ventilation for more than 48h before COVID epidemic, for any reason other than viral pneumonia are eligible for this group. The number of included patients in this group will be similar as that of patients included in the SARS-CoV-2 group in the same center (10-20 patients) These consecutive patients will be included starting at the end of January 2020 and going back to 2019 if necessary. VAT and VAP are defined using clinical, radiological and quantitative microbiological criteria.

Study Type

Observational

Enrollment (Actual)

1576

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Lille, France, 59037
        • Hôpital Roger Salengro, ICU, CHU Lille

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

patients suspected of pulmonary infection and admitted in ICU

Description

Inclusion Criteria:

For all three groups:

  • Major patient
  • In patients in ICU
  • Patients intubated and mechanically ventilated for more than 48 hours.

For the SARS-CoV2 group: community-acquired SARS-CoV2 pneumonia For the influenza group: community-acquired influenza pneumonia For the "No Viral Infection" group: no viral pneumonia on admission.

Exclusion Criteria:

  • Refusal to participate
  • Lack of social security coverage

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
SARS-CoV2 group
Patients receiving invasive mechanical ventilation for more than 48h with SARS-CoV-2 infection
Flu group
Patients receiving invasive mechanical ventilation for more than 48h with influenza infection
No viral infection group
Patients receiving invasive mechanical ventilation for more than 48h with no viral infection at ICU admission

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cumulative incidence of ventilator-associated lower respiratory tract infection
Time Frame: from day 3 of mechanical ventilation to extubation or day 28 post-intubation.
the incidence of ventilator associated pneumonia and ventilator associated tracheobronchitis
from day 3 of mechanical ventilation to extubation or day 28 post-intubation.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cumulative incidence of ventilator-associated tracheobronchitis
Time Frame: from day 3 of mechanical ventilation to extubation or day 28 post intubation
incidence of ventilator-associated tracheobronchitis
from day 3 of mechanical ventilation to extubation or day 28 post intubation
Cumulative incidence of ventilator-associated pneumonia
Time Frame: from Day 3 of mechanical ventilation to extubation or day 28 post intubation.
incidence of ventilator-associated pneumonia
from Day 3 of mechanical ventilation to extubation or day 28 post intubation.
the cumulative incidence of ICU acquired bacteremia diagnosed
Time Frame: from ICU admission to extubation or Day 28.
incidence of ICU-acquired bacteremia
from ICU admission to extubation or Day 28.
ICU mortality
Time Frame: at day 28
death in the ICU
at day 28
Mortality
Time Frame: at day 28
death
at day 28
the duration of mechanical ventilation
Time Frame: from the start of mechanical ventilation to extubation or day 28 post intubation
number of days Under mechanical ventilation
from the start of mechanical ventilation to extubation or day 28 post intubation
Length of stay in Intensive Care Unit
Time Frame: from admission to ICU until extubation or Day 28
number of days in the ICU
from admission to ICU until extubation or Day 28

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Lille

Investigators

  • Principal Investigator: Saad NSEIR, MD,PhD, University Hospital, Lille

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 22, 2020

Primary Completion (Actual)

July 1, 2020

Study Completion (Actual)

July 1, 2020

Study Registration Dates

First Submitted

April 21, 2020

First Submitted That Met QC Criteria

April 21, 2020

First Posted (Actual)

April 24, 2020

Study Record Updates

Last Update Posted (Actual)

April 22, 2026

Last Update Submitted That Met QC Criteria

April 17, 2026

Last Verified

July 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2020_27
  • 2020-A00995-34 (Other Identifier: ID-RCB number,ANSM)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on SARS-CoV 2

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe